Stryker Corporation (SYK) Cash Flow Statement

The wide quarterly swings in OCF/NI, from 0.26 to 3.54, suggest that reported earnings are not consistently translating into cash, with working capital changes being the primary driver. For instance, 2026Q1 saw a negative working capital change of $560M, compressing OCF to $581M against net income of $745M, while 2025Q4 benefited from a $709M positive working capital swing. This pattern implies that investors should focus on annualized cash conversion rather than quarterly figures, as the underlying earnings quality appears stable but timing effects are pronounced.

The FCF trajectory shows a strong seasonal pattern, with Q4 typically generating the highest FCF (e.g., $1.9B in 2025Q4) and Q1 the weakest (e.g., $127M in 2025Q1). The 2026Q2 FCF of $1.1B is a solid improvement, but the margin of 16.1% is still below the 25.9% achieved in 2024Q4, suggesting that growth investments or working capital needs may be tempering cash generation. Compared to peers like Zimmer Biomet's 26.5% FCF margin, Stryker's recent quarterly margins appear lower, though the company's scale and growth profile may justify higher reinvestment.

CapEx as a percentage of revenue has been remarkably stable, ranging from 2.1% to 4.1%, with no clear upward trend despite revenue growth. This suggests that Stryker's growth is not heavily dependent on fixed asset expansion, and the moderate capital intensity allows for substantial free cash flow generation. The consistency of CapEx relative to revenue implies that maintenance and growth capex are well balanced, and the company may be able to sustain its current investment levels without straining cash flow.

The extreme swings in working capital, particularly in Q1 quarters (e.g., -$895M in 2024Q1 and -$892M in 2025Q1), suggest a seasonal pattern where the company builds inventory or extends receivables early in the year, then collects in later quarters. This pattern is typical for medical device companies with new product launches and hospital purchasing cycles. The magnitude of these swings, however, is substantial relative to quarterly net income, indicating that working capital management is a key lever for cash flow timing and may warrant close monitoring for any structural deterioration.

Stryker's capital deployment shows a consistent commitment to returning cash to shareholders via dividends, with quarterly payments stable around $305-337M. However, the most striking feature is the $4.7B net cash outflow for acquisitions in 2025Q1, which dwarfs quarterly FCF and suggests a significant M&A-driven strategy. This heavy acquisition activity may explain the occasional negative free cash flow quarters and the need to maintain a healthy balance sheet. The company also engages in modest buybacks, but they are not a primary use of cash, indicating a preference for reinvestment and dividends.

The cumulative OCF of $11.1B versus net income of $8.1B over the ten-quarter period shows that Stryker's cash generation has been robust, with the gap largely attributable to non-cash charges like D&A and favorable working capital timing. This suggests that the company's earnings quality is high, and the occasional quarterly shortfalls are not indicative of a systemic issue. The divergence also implies that Stryker has ample internal funding for its dividend and acquisition strategy, reducing reliance on external financing.